Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT
Open Access
- 3 December 2009
- journal article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 28 (1) , 147
Abstract
Antibody Directed Enzyme Prodrug Therapy (ADEPT) can be used to generate cytotoxic agents at the tumor site. To date non-human enzymes have mainly been utilized in ADEPT. However, these non-human enzymes are immunogenic limiting the number of times that ADEPT can be administered. To overcome the problem of immunogenicity, a fully human enzyme, capable of converting a non-toxic prodrug to cytotoxic drug was developed and joined to a human tumor specific scFv yielding a fully human targeting agent.Keywords
This publication has 27 references indexed in Scilit:
- Structure of a mutant human purine nucleoside phosphorylase with the prodrug, 2‐fluoro‐2′‐deoxyadenosine and the cytotoxic drug, 2‐fluoroadenineProtein Science, 2009
- Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapyMolecular Cancer Therapeutics, 2009
- Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancerMolecular Cancer Therapeutics, 2009
- A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus ApproachPLOS Computational Biology, 2008
- Structure of human PNP complexed with ligandsActa Crystallographica Section D Structural Biology, 2005
- Excellent In vivo Bystander Activity of Fludarabine Phosphate against Human Glioma Xenografts that Express the Escherichia coli Purine Nucleoside Phosphorylase GeneCancer Research, 2004
- Proteolytic Sensitivity and Helper T-cell Epitope Immunodominance Associated with the Mobile Loop in Hsp10sJournal of Biological Chemistry, 2002
- Disabling ErbB Receptors with Rationally Designed Exocyclic Mimetics of Antibodies: Structure−Function AnalysisJournal of Medicinal Chemistry, 2001
- Prodrug-activating systems in suicide gene therapyJournal of Clinical Investigation, 2000
- Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding SiteJournal of Molecular Biology, 1996